Novanta (NASDAQ:NOVT – Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of $0.9670 per share and revenue of $301.02 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.
Novanta (NASDAQ:NOVT – Get Free Report) last announced its earnings results on Wednesday, August 5th. The technology company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.06. Novanta had a return on equity of 10.83% and a net margin of 6.00%. The company had revenue of $265.81 million for the quarter, compared to analyst estimates of $262.30 million. During the same period in the prior year, the company posted $0.76 EPS. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts expect Novanta to post $3.70 EPS for the current fiscal year and $4.33 EPS for the next fiscal year.
Novanta Trading Up 2.5%
Novanta stock opened at $135.15 on Friday. The stock has a 50-day moving average of $142.18 and a two-hundred day moving average of $142.57. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.79 and a current ratio of 4.57. Novanta has a one year low of $98.27 and a one year high of $176.38. The stock has a market cap of $5.11 billion, a PE ratio of 86.64 and a beta of 1.71.
Analyst Ratings Changes
View Our Latest Report on NOVT
Novanta Company Profile
Novanta Inc is a technology company that develops and manufactures precision equipment and components used primarily in medical and advanced industrial applications. Its solutions are designed to support the movement, imaging, measurement and processing functions of complex equipment.
The company’s products include photonics and laser components, precision motion-control systems, medical imaging and visualization technologies, and equipment used in minimally invasive and robotic surgery.
Featured Stories
- Five stocks we like better than Novanta
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
